Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
$0.01
Change (1 day)
$8.10
Year High
$5.00
Year Low
Categories
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.1 B | -2,911,299,137 | 387.51 M | 6.17 B | 4.41 B |
| 2022 | 1.4 B | -1,936,677,150 | 555.17 M | 5.97 B | 4.36 B |
| 2021 | 1.2 B | -1,898,418,481 | 520.32 M | 5.53 B | 4.25 B |
| 2020 | 1.32 B | -1,296,165,288 | 555.28 M | 4.89 B | 3.95 B |
| 2019 | 974.66 M | -651,217,634 | 368.85 M | 3.88 B | 3.14 B |